| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/096368970000900212 |
| P698 | PubMed publication ID | 10811399 |
| P50 | author | Ole Isacson | Q67215582 |
| P2093 | author name string | Shannon K | |
| Fischman AJ | |||
| Penn R | |||
| Raineri R | |||
| Fink JS | |||
| Starr P | |||
| Palmer EP | |||
| Schumacher JM | |||
| Dempsey PK | |||
| Dinsmore J | |||
| Manhart C | |||
| Saint-Hilaire M | |||
| Kott HS | |||
| Ellias SL | |||
| VanHorne C | |||
| P2860 | cites work | Infection of human cells by an endogenous retrovirus of pigs | Q34418546 |
| P433 | issue | 2 | |
| P921 | main subject | xenograft | Q64148587 |
| Huntington's disease | Q190564 | ||
| Parkinson's disease | Q11085 | ||
| P304 | page(s) | 273-278 | |
| P577 | publication date | 2000-03-01 | |
| P1433 | published in | Cell Transplantation | Q15761863 |
| P1476 | title | Porcine xenografts in Parkinson's disease and Huntington's disease patients: preliminary results | |
| P478 | volume | 9 |
| Q57178432 | Advances in the discovery of genetic risk factors for complex forms of neurodegenerative disorders: contemporary approaches, success, challenges and prospects |
| Q92131901 | Advantages and Recent Developments of Autologous Cell Therapy for Parkinson's Disease Patients |
| Q40739191 | Application of hollow fiber vitrification for cryopreservation of bovine early cleavage stage embryos and porcine morula-blastomeres |
| Q35595366 | Application of transgenesis in livestock for agriculture and biomedicine |
| Q35209105 | CNS regeneration: clinical possibility or basic science fantasy? |
| Q36045364 | Cell therapy in Huntington's disease. |
| Q33818127 | Cell-based therapies for Parkinson's disease: past, present, and future |
| Q41829129 | Certain promise and uncertain peril. The debate on xenotransplantation |
| Q35789004 | Clonal human (hNT) neuron grafts for stroke therapy: neuropathology in a patient 27 months after implantation |
| Q40583619 | Complications of a trophic xenotransplant approach in parkinsonian monkeys |
| Q39154189 | Concise Review: Innate and Adaptive Immune Recognition of Allogeneic and Xenogeneic Cell Transplants in the Central Nervous System. |
| Q39602639 | Detection and characterization of porcine endogenous retrovirus in porcine plasma and porcine factor VIII |
| Q38105080 | Devices for cell transplantation into the central nervous system: Design considerations and emerging technologies |
| Q34657662 | Dopaminergic cells of the carotid body: physiological significance and possible therapeutic applications in Parkinson's disease. |
| Q44722641 | Effects of Sertoli cell transplants in a 3-nitropropionic acid model of early Huntington's disease: a preliminary study |
| Q33844988 | Embryonic pig liver, pancreas, and lung as a source for transplantation: optimal organogenesis without teratoma depends on distinct time windows |
| Q58668448 | Ethical guidance on human embryonic and fetal tissue transplantation: a European overview |
| Q37930039 | Experimental Models of HD and Reflection on Therapeutic Strategies |
| Q37825629 | Experimental Surgical Therapies for Huntington's Disease |
| Q47400314 | Functional integration of embryonic stem cell-derived neurons in vivo. |
| Q41563981 | Gene Editing, Gene Therapy, and Cell Xenotransplantation: Cell Transplantation Across Species. |
| Q40638329 | Gene therapy for experimental brain tumors using a xenogenic cell line engineered to secrete hIL-2. |
| Q33960096 | Gene therapy in epilepsy |
| Q44472641 | Human natural killer cell activity against porcine targets: modulation by control of the oxidation-reduction environment and role of adhesion molecule interactions |
| Q26826905 | Immune modulation in xenotransplantation |
| Q36045396 | Immune problems in central nervous system cell therapy. |
| Q35940563 | Infection Barriers to Successful Xenotransplantation Focusing on Porcine Endogenous Retroviruses |
| Q39566277 | Injection Parameters Affect Cell Viability and Implant Volumes in Automated Cell Delivery for the Brain |
| Q44193661 | Intracranial delivery of stem cells |
| Q64271053 | Intravesical Administration of Xenogeneic Porcine Urothelial Cells Attenuates Cyclophosphamide-Induced Cystitis in Mice |
| Q33999256 | Large animal models are critical for rationally advancing regenerative therapies |
| Q43804623 | Liposomal Tacrolimus Administered Systemically and within the Donor Cell Suspension Improves Xenograft Survival in Hemiparkinsonian Rats |
| Q34054806 | Literature update 2000, part 1. |
| Q34885388 | Local control of the host immune response performed with mesenchymal stem cells: perspectives for functional intracerebral xenotransplantation |
| Q40431597 | Long distance selective fiber outgrowth of transplanted hNT neurons in white matter tracts of the adult rat brain |
| Q82602837 | Manual Vs Automated Delivery of Cells for Transplantation: Accuracy, Reproducibility, and Impact on Viability |
| Q34120779 | Neural transplantation for the treatment of Huntington's disease |
| Q35172255 | Neural transplantation for the treatment of Parkinson's disease |
| Q34731427 | Neural transplantation for treatment of Parkinson's disease. |
| Q48867453 | Neural transplantation therapies for Parkinson's and Huntington's diseases. |
| Q48269394 | Neurobehavioral assessment of transplanted porcine Sertoli cells into the intact rat striatum |
| Q38733015 | Patients with ALS show highly correlated progression rates in left and right limb muscles |
| Q48526383 | Pig Neural Cells Derived from Foetal Mesencephalon as Cell Source for Intracerebral Xenotransplantation |
| Q55279466 | Porcine Endogenous Retrovirus (PERV) - Molecular Structure and Replication Strategy in the Context of Retroviral Infection Risk of Human Cells. |
| Q80213308 | Porcine cell microchimerism but lack of productive porcine endogenous retrovirus (PERV) infection in naive and humanized SCID-beige mice treated with porcine peripheral blood mononuclear cells |
| Q39685877 | Porcine endogenous retrovirus infects but does not replicate in nonhuman primate primary cells and cell lines |
| Q33677528 | Porcine endogenous retroviruses in xenotransplantation--molecular aspects |
| Q36045402 | Positron emission tomography imaging of transplant function. |
| Q44209103 | Rat nigral xenografts survive in the brain of MHC class II-, but not class I-deficient mice |
| Q35597607 | The Current Status of Neural Grafting in the Treatment of Huntington's Disease. A Review |
| Q35781261 | The cellular repair of the brain in Parkinson's disease--past, present and future. |
| Q38004257 | The immunological challenges of cell transplantation for the treatment of Parkinson's disease. |
| Q36045254 | The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration |
| Q24239973 | Therapeutic interventions for disease progression in Huntington's disease |
| Q24799127 | Tissue engineering and cell based therapies, from the bench to the clinic: the potential to replace, repair and regenerate |
| Q37870829 | To be or not to be accepted: the role of immunogenicity of neural stem cells following transplantation into the brain in animal and human studies. |
| Q40384077 | Transgenic expression of CTLA4-Ig by fetal pig neurons for xenotransplantation. |
| Q38289368 | Transgenic pigs designed to express human CD59 and H-transferase to avoid humoral xenograft rejection |
| Q48769080 | Transplantation of brain cells assembled around a programmable synthetic microenvironment |
| Q49679207 | Xenogeneic cell therapy provides a novel potential therapeutic option for cancers by restoring tissue function, repairing cancer wound and reviving anti-tumor immune responses |
| Q34273379 | Xenotransplantation: An Overview of the Field |
| Q35861536 | Xenotransplantation: infectious risk revisited |
| Q43215028 | Xenotransplantation: reappraising the risk of retroviral zoonosis |
| Q34280315 | Xenotransplantation: regulatory challenges |
Search more.